El papel de los biosimilares en la enfermedad inflamatoria intestinal: una realidad en nuestro país

El papel de los biosimilares en la enfermedad inflamatoria intestinal: una realidad en nuestro país

La Enfermedad Inflamatoria Intestinal (EEI) es un término con el que se conocen varias entidades, las dos más importantes: la Colitis Ulcerativa Idiopática (CUI) y la Enfermedad de Crohn (EC), cuyo origen es multifactorial y se caracterizan por un fenómeno inflamatorio, crónico, recurrente con dife...

Full description

Saved in:

Bibliographic Details
Main Authors:	Juan Ricardo Márquez Velásquez, Fernando Gomollón García
Format:	Article
Language:	English
Published:	Asociación Colombiana de Gastroenterología 2017-12-01
Series:	Revista Colombiana de Gastroenterología
Subjects:	Biosimilares agentes biológicos anti TNF extrapolación sustitución e intercambiabilidad
Online Access:	https://revistagastrocolcom.biteca.online/index.php/rcg/article/view/174
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Lo que debe saber el dermatólogo sobre los medicamentos biológicos y los biosimilares
by: Gloria Sanclemente
Published: (2019-03-01)

¿Debemos las Sociedades Científicas participar en los Procesos Regulatorios de los Medicamentos Biológicos y Biosimilares?
by: CESAR BURGOS
Published: (2019-08-01)

BIOSIMILARS IN RHEUMATOLOGY
by: E. L. Nasonov
Published: (2017-01-01)

Options to optimize the access to biosimilars: analysis and solutions
by: O. V. Kirsanova, et al.
Published: (2018-05-01)

Approaches to resolve practical challenges in the context of assessing the price of biosimilar products
by: A. H.-M. Valeeva, et al.
Published: (2025-01-01)

Biosimilares – Nuestro futuro próximo
by: Natalia Hernández M.
Published: (2018-11-01)

Perception toward Biosimilars and Nonmedical Switching: A Cross-sectional Survey among Arab Rheumatologists
by: Mohammed A. Omair, et al.
Published: (2020-10-01)

INTERNATIONAL APPROACHES TO THE GOVERNMENT PRICE CONTROL OVER GENERICS AND BIOSIMILARS: A REVIEW
by: D. G. Tolkacheva, et al.
Published: (2018-02-01)

First available biosimilar monoclonal antibodies
by: Zh. I. Avdeeva, et al.
Published: (2018-02-01)

Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study
by: W. H. A. van Poecke, et al.
Published: (2025-07-01)

Biosimilars - drugs of the future
by: E. A. Eltcova, et al.
Published: (2014-04-01)

Harina de plátano (MUSA PARADISIACA L.) en combinación con harina de maíz, para la elaboración de tortillas
by: Mariliana Videa Bustillo, et al.
Published: (2018-12-01)

Comparative efficacy and safety of adalimumab biosimilar (BCD-057) and innovator in patients with psoriasis vulgaris. Results of the BCD-057-2/CALYPSO phase III international, multicenter, randomized double-blind clinical trial
by: Т. V. Korotaeva, et al.
Published: (2018-12-01)

ECONOMIC ASPECTS OF APPLICATION OF THE RUSSIAN BIOSIMILAR OMALIZUMAB IN PATIENTS WITH ATOPIC BRONCHIAL ASTHMA OF MODERATE TO SEVERE CLINICAL COURSES
by: V. S. Krysanova, et al.
Published: (2021-08-01)

La Educación Mediática en Nuestro Entorno: Realidades y Posibles Mejoras
by: Juan de Pablos Pons, et al.
Published: (2018-01-01)

A comprehensive evaluation of the transition to a biosimilar of adalimumab in rheumatoid arthritis and psoriatic arthritis: a single-center experience with a focus on imaging outcomes
by: Rodrigo Garcia-Salinas, et al.
Published: (2025-05-01)

Transitioning from Aflibercept to Biosimilar Ranibizumab in Diabetic Macular Edema (DME): (The TRANSFORM-DME Trial) a Multicenter Observational Study
by: Chakraborty D, et al.
Published: (2024-11-01)

Comparative efficacy and safety of infliximab biosimilar (BCD-055) and innovator infliximab in patients with ankylosing spondylitis (results of international, multiple-center, double-blind phase I and phase III clinical studies)
by: D. E. Karateev, et al.
Published: (2017-09-01)

SAFETY STUDY OF ROMIPLOSTIM BIOSIMILAR
by: A. N. Afanasyeva, et al.
Published: (2022-10-01)

COMPARATIVE EVALUATION OF THE LONG-TERM EFFICACY AND SAFETY OF THE INFLIXIMAB BIOSIMILAR BCD-055 AND REFERENCE INFLIXIMAB IN PATIENTS WITH ANKYLOSING SPONDYLITIS: RESULTS OF THE INTERNATIONAL MULTICENTER RANDOMIZED DOUBLE-BLIND PHASE III CLINICAL STUDY ASART-2
by: A. M. Lila, et al.
Published: (2018-07-01)

Physico-Chemical and Biological Properties of Biosimilar and Reference Tissue Plasminogen Activator Products
by: V. D. Gusarova, et al.
Published: (2019-03-01)

Erelzi<sup>®</sup> – biosimilar of etanercept in the treatment of rheumatic diseases and psoriasis (Resolution of the Expert Panel)
by: V. I. Mazurov, et al.
Published: (2021-08-01)

Contextual factors in value-based decision support to enhance health technologies adoption: the case of biosimilars
by: Maximilian Otte, et al.
Published: (2025-08-01)

La consolidación del ambiente obesogénico en México
by: Alejandro Martínez Espinosa
Published: (2017-01-01)

Results of the Estimation of Biosimilarity of RinLiz<sup>®</sup> (LLC «GEROPHARM», Russia) and Humalog<sup>®</sup> (Lilly France, France) Using the Method of the Hyperinsulinemic Eulygemic Clamp on Healthy Voluntary
by: A. Yu. Mayorov, et al.
Published: (2020-05-01)

An observational study «FOLLITROPIN» comparing the efficacy of follitropin alpha biosimilar: the real-world data
by: D. P. Kamilova, et al.
Published: (2021-03-01)

The interchangeability of original tumor necrosis factor- α inhibitors and biosimilars in rheumatology: experience in replacing original infliximab with Flammagis for ankylosing spondylitis
by: Yu. V. Muravyev, et al.
Published: (2020-05-01)

Arthropod bioindicators of environmental quality
by: Márcia Soares Spiller, et al.
Published: (2017-12-01)

Efeito nematicida do fungo Duddingtonia flagrans em ovinos
by: Marcio da Silva Chaves, et al.
Published: (2024-08-01)

Llamada para discutir una brecha de seguridad microbiológica
by: Carlota Alejandre Colomo, et al.
Published: (2025-05-01)

Miseria en el hogar: el encierro domiciliario de las mujeres detenidas por delitos relacionados con las drogas en Medellín
by: Libardo José Ariza, et al.
Published: (2020-11-01)

Principales microorganismos entomopatógenos de Tecia solanivora y sus mecanismos de acción
by: Emmanuel Guerra-Luran, et al.
Published: (2021-03-01)

Processamento auditivo central e compreensão leitora
by: Costa, Maria Inês Dornelles da
Published: (2003-01-01)

Development and Validation of the ELISA Method for Anti-trastuzumab Antibodies Determination in Human Serum
by: O. A. Eliseeva, et al.
Published: (2022-12-01)

Enfermedad inflamatoria intestinal: características de fenotipo y tratamiento en un hospital universitario de Bogotá, Colombia.
by: Gustavo Adolfo Reyes Medina, et al.
Published: (2018-07-01)

Vías inflamatorias en la fisiopatología del acné
by: Beatriz Orozco, et al.
Published: (2013-10-01)

Toxicity Associated with Immune Checkpoint Inhibitors: Analysis of Immune-Related Adverse Events with a Pembrolizumab Biosimilar (Pembroria)
by: M. Yu. Fedyanin, et al.
Published: (2023-06-01)

Estequiometria da remoção convencional de nitrogênio em sistemas de lodo ativado
by: Adrianus van Haandel, et al.
Published: (2025-07-01)

Biosimilar of biphasic human insulin: results of a double-blind, randomized, comparative, cross-sectional clinical study of pharmacokinetics
by: Tatyana Karonova, et al.
Published: (2019-09-01)

Uso de probióticos en síndrome de intestino irritable y enfermedad inflamatoria intestinal: una revisión de la literatura
by: Jeanette Coriat B, et al.
Published: (2017-07-01)